title: Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
abstract: We evaluate the efficacy and toxicities of low-dose FP therapy in the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. 104 patients (gastric adenocarcinoma: 52, colorectal adenocarcinoma: 52) were enrolled. Low-dose FP therapy consisted of 5-FU (160 mg/m2/day every day by continuous infusion) and cisplatin (3 mg/m2/day in 100 ml of normal saline by infusion over 30 minutes on days 1-5/W). Patients were treated for 4 consecutive weeks with subsequent one-week rest period. Ninety-four of 104 patients completed this therapy, and the treatment accomplishment rate was 90%; 82% in gastric adenocarcinomas, 96% in colorectal adenocarcinomas. Two cases had CR, and 47 cases had PR, with an overall response rate of 52.1%. Response rates, 50% survival time, 1-year survival rates, and 2-year survival rates were 65.9%, 249 days, 33.7%, 19.7% in gastric adenocarcinomas, and 40.0%, 466 days, 56.7%, 29.4% in colorectal adenocarcinomas, respectively. Nausea/vomiting was the most common toxicity, occurring in 44.2% of patients treated and was predominantly mild to moderate (up to Grade 2). In 5 cases Grade 3 toxicity was observed. Low-dose FP therapy has a high antineoplastic effect and low-grade toxicity, and this therapy should become the first-choice chemotherapy for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
authors.affiliation: Clinical Oncology Group (Internal Medicine, Radiology, Surgery, Gastroenterology), Kochi Municipal Central Hospital.
authors.forename: A
authors.initials: A
authors.lastname: Tsuji
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.forename: T
authors.initials: T
authors.lastname: Horimi
authors.forename: M
authors.initials: M
authors.lastname: Takasaki
authors.forename: I
authors.initials: I
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Shirasaka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014840:Vomiting, Anticipatory / Q000209:etiology
chemical_list: D002945:Cisplatin; D005472:Fluorouracil